title: A novel peroxisome proliferator-activated receptor (PPAR)gamma agonist, NIP-222, reduces urinary albumin excretion in streptozotocin-diabetic mice independent of PPARgamma activation.
abstract: NIP-222 is a novel peroxisome proliferator-activated receptor (PPAR)gamma agonist. This study provides evidence that NIP-222 decreases urinary albumin excretion (UAE) in diabetic mice independent of its PPARgamma activation. We compared the effect of NIP-222 and another PPARgamma agonist, troglitazone, on UAE, plasma glucose level, blood pressure, and creatinine clearance (C(cr)) in streptozotocin (STZ)-induced diabetic mice. Treatment for 3 weeks with NIP-222 (30 mg/kg) was associated with a significant decrease in UAE without any change in blood pressure, creatinine clearance, or plasma glucose level. In contrast, UAE did not decrease in mice treated with troglitazone (300 mg/kg). These results indicate that NIP-222 has PPARgamma independent effects on UAE in diabetic mice and suggest that this agent may have potential to minimize the development and progression of diabetic nephropathy.
authors.affiliation: Biological Research Laboratories, Nissan Chemical Industries Ltd, Minamisaitama, Saitama, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Yotsumoto
authors.forename: Takeshi
authors.initials: T
authors.lastname: Naitoh
authors.forename: Tatsuro
authors.initials: T
authors.lastname: Kanaki
authors.forename: Maho
authors.initials: M
authors.lastname: Matsuda
authors.forename: Nobutomo
authors.initials: N
authors.lastname: Tsuruzoe
mesh_terms: D000419:Albuminuria / Q000150:complications / Q000188:drug therapy*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002216:Captopril / Q000494:pharmacology; D002839:Chromans / Q000494:pharmacology; D003921:Diabetes Mellitus, Experimental / Q000150:complications* / Q000652:urine; D003924:Diabetes Mellitus, Type 2 / Q000235:genetics / Q000378:metabolism; D003928:Diabetic Nephropathies / Q000378:metabolism / Q000473:pathology; D017930:Genes, Reporter / Q000235:genetics; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D008156:Luciferases / Q000235:genetics; D008297:Male; D051379:Mice; D009929:Organ Size / Q000187:drug effects; D010957:Plasmids / Q000235:genetics; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists* / Q000378:metabolism*; D045162:Thiazolidinediones / Q000494:pharmacology; D014157:Transcription Factors / Q000819:agonists* / Q000378:metabolism*; D000077288:Troglitazone; D014563:Urodynamics / Q000187:drug effects
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D001786:Blood Glucose; D002839:Chromans; D007004:Hypoglycemic Agents; C481201:NIP-222; D018160:Receptors, Cytoplasmic and Nuclear; D045162:Thiazolidinediones; D014157:Transcription Factors; D002216:Captopril; D008156:Luciferases; D000077288:Troglitazone